Cavendish class 3 new drug pomadolamine capsule has been applied for clinical acceptance

According to the information on the website of the State Food and Drug Administration (CFDA) on July 18, Nanjing Cavendish Bioengineering Technology Co., Ltd., a subsidiary of Shuanglu Pharmaceutical Co., Ltd., has accepted the application for the clinical application of three new drugs, pomadomide capsule, which is the first anti-cancer drug of dumadomide to be imitated by the company after coming to nadadomide Pamidramine is the third amine after thalidomide and lenalidomide in the treatment of multiple myeloma Pamidramine has antitumor activity, can inhibit the proliferation of hematopoietic tumor cells and induce apoptosis, and can inhibit the proliferation of multiple myeloma cell lines resistant to lenalidomide There are also many side effects There is a black box warning in the drug manual We should be alert to embryo fetal toxicity, blood toxicity, nervous system toxicity and the risk of second primary malignant tumor Pomadoxamine was developed by celgene in the United States It was approved to be listed through the FDA's accelerated approval process in February 2013 At present, there are no domestic manufacturers However, companies with strong R & D capabilities such as Zhengda Tianqing, aosaikang, and Jiangsu Haosen have joined the competition with Shuanglu pharmaceutical industry for the first time Cavendish, a subsidiary of Shuanglu pharmaceutical, has long been in the distribution of diamine drugs Lainadua is the first generic drug that the company challenges patent, and the company has high hopes The company said on the interactive platform that the drug will be applied for production in the near future, and it is expected to get production approval documents in June and July next year.